Navigation Links
Jiangbo Pharmaceuticals to Attend the 44th China New Drugs Trade Fair in Tianjin
Date:6/18/2009

LAIYANG, China, June 18 /PRNewswire-Asia-FirstCall/ -- Jiangbo Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: JGBO) (the "Company", "Jiangbo"), a U.S. pharmaceutical company with its principal operations in the People's Republic of China, today announced that it will attend the China New Drugs Trade Fair from June 26 to 28, 2009 at Tianjin Binhai International Convention & Exhibition Center, and also plans to launch a new promotional campaign for its recently acquired Laiyang Pear Cough Syrup.

Jiangbo plans to promote its brand at the trade fair to increase the popularity of its Traditional Chinese Medicine (TCM) products. The Company will promote the portfolio of TCM products it acquired by purchasing Hongrui Pharmaceutical Company in early 2009 to its existing customers, and speak with new potential distributors.

Laiyang City is famous for its pears. "Laiyang Pear" is a trademark for place of origin which is registered with the Chinese National Industrial and Commercial Bureau. In production by Jiangbo since April of 2009, Laiyang Pear Cough Syrup is made from Laiyang Pears and is used to relieve coughs and remove phlegm arising from colds or other ailments. The Company believes that Laiyang Pear Cough Syrup tastes much better than alternative cough syrups. The cough syrup's pear taste makes it especially popular among children.

As a leading manufacturer using Laiyang Pears in a cough syrup, Jiangbo intends to leverage its location in Laiyang and extensive sales network to become the market leader for this type of cough syrup.

"We look forward to attending the trade fair. We plan to renew old contacts, and hope to develop new relationships with distributors through which we will increase our TCM sales," said Mr. Wubo Cao, CEO of Jiangbo. "Separately, we plan to start an active promotional campaign for our Laiyang Pear Cough Syrup. The current market size for cough syrups in China is approximately RMB 5 to 10 billion annually and is rapidly growing. We currently estimate that our sales of Laiyang Pear Cough Syrup in China will reach RMB 500 million within the next five years."

About the 44th China New Drugs Trade Fair

The China New Drugs Trade Fair is a professional forum for individuals and companies interested in commercializing drugs and new pharmaceutical products in China. The event will be held June 26 to 28 at the Binhai International Convention & Exhibition Center in Tianjin, China. The trade fair plays an important role in connecting "Government, industry, academic research, funding and service." More than 70,000 professionals are expected to attend the trade fair. For more information about the China New Drugs Trade Fair, please visit http://en.newdrugschina.com .

About Jiangbo Pharmaceuticals, Inc.

Jiangbo Pharmaceuticals, Inc. is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Its operations are located in Eastern China in an Economic Development Zone in Laiyang City, Shandong province. Jiangbo is a major pharmaceutical company in China producing both western and Chinese herbal-based medical drugs in tablet, capsule, granule, syrup and electuary (sticky syrup) form. http://www.jiangbopharma.com

Safe Harbor Statement

Certain statements in this press release that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are not guarantees of future performance and are subject to risks and uncertainties that could cause the Company's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from anticipated or predicted results, and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's ability to obtain raw materials needed in manufacturing, the continuing employment of key employees, the failure risks inherent in testing any new drug, the possibility that regulatory approvals may be delayed or become unavailable, patent or licensing concerns that may include litigation, direct competition from other manufacturers and product obsolescence. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

    For more information, please contact:

    Jiangbo Pharmaceuticals, Inc.
     Ms. Elsa Sung, CFO
     Phone: +1-954-727-8435
     Email: elsasung@jiangbo.com
    http://www.jiangbopharma.com

    CCG Investor Relations, Inc.
     Mr. Crocker Coulson, President
     Phone: +1-646-213-1915
     Email: crocker.coulson@ccgir.com
    http://www.ccgirasia.com

'/>"/>
SOURCE Jiangbo Pharmaceuticals Enterprises, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genesis Pharmaceuticals Changes its Name to Jiangbo Pharmaceuticals, Inc. to Reflect its Brand Name
2. Jiangbo Pharmaceuticals Announces New Ticker (JGBO) and CUSIP
3. Jiangbo Pharmaceuticals, Inc. to Present at CCG IRs China Rising Conference in New York
4. Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for its Third Quarter of FY 2009
5. Jiangbo Pharmaceuticals Reports Results for the Third Quarter of its Fiscal Year 2009
6. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
10. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
11. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... More than 20,000 pairs of ... Congo (DRC) thanks to an ambitious venture that conjoined the passions of an NBA ... support of the Liberty community. These shoes will save lives from the rampant infections ...
(Date:8/18/2017)... ... August 18, 2017 , ... Mediaplanet today announces the launch ... lifestyles and highlighting the importance of proactive eye and ear health. The campaign ... latest innovations in hearing aid technology. , In this issue, the National ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... handling handheld devices. Through an educational webinar, they will present the line of ... chance to learn how easy you can automate everyday pipetting tasks. , Ideal ...
(Date:8/18/2017)... ... 2017 , ... Radabaugh & Associates, a family managed agency ... West Virginia, is embarking on a cooperative charity effort with the Chestnut Mountain ... Chestnut Mountain Ranch (CMR) is a Christ-centered boarding school for young men offering ...
(Date:8/18/2017)... ... August 18, 2017 , ... The Brian Gifford Agency, an ... is campaigning in support of Campagna Academy in a charity drive to provide for ... Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that has offered critical ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... AccuGenomics, Inc., a diagnostic company based in ... the company has provided an AccuKit to the HIV ... Chapel Hill and to Qura Therapeutics for evaluation in ... HIV reservoir and viral expression in human CD4+ T ... Center is a joint initiative between the University of ...
(Date:8/8/2017)... Aug. 8, 2017  BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... reports its financial results for the second quarter ended ... the second quarter 2017 and to date: ... development programs for the Company,s lead project, BL-8040: ... study with BL-8040 as novel stem cell mobilization treatment ...
(Date:8/7/2017)... 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the nation,s largest ... June 30, 2017.  All comparisons, unless otherwise noted, are to ... Second Quarter 2017 Highlights include: ... an increase of 3.5% Total prescriptions dispensed ... of 7.5% versus 7.6% Gross profit ...
Breaking Medicine Technology: